



## Clinical trial results:

### A Randomized, Double-blind, Parallel-group Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants with Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment

#### Summary

|                          |                |
|--------------------------|----------------|
| EudraCT number           | 2019-003369-16 |
| Trial protocol           | ES PL          |
| Global end of trial date | 16 March 2022  |

#### Results information

|                                |   |
|--------------------------------|---|
| Result version number          | v2 (current)  |
| This version publication date  | 09 July 2023  |
| First version publication date | 01 April 2023   |
| Version creation reason        | <ul style="list-style-type: none"><li>• New data added to full data set</li></ul> New data were included in the Adverse Event section |

#### Trial information

##### Trial identification

|                       |           |
|-----------------------|-----------|
| Sponsor protocol code | GWAP19030 |
|-----------------------|-----------|

##### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT04421456 |
| WHO universal trial number (UTN)   | -           |

Notes:

#### Sponsors

|                              |  |
|------------------------------|--|
| Sponsor organisation name    | GW Research Ltd  |
| Sponsor organisation address | Sovereign House, Vision Park, Histon, Cambridge, United Kingdom, CB24 9BZ  |
| Public contact               | Clinical Trial Disclosure & Transparency, GW Research Ltd, +1 215-832-3750, ClinicalTrialDisclosure@JazzPharma.com |
| Scientific contact           | Clinical Trial Disclosure & Transparency, GW Research Ltd, +1 215-832-3750, ClinicalTrialDisclosure@JazzPharma.com |

Notes:

#### Paediatric regulatory details

|  |    |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|  |               |
|--|---------------|
| Analysis stage                                       | Final         |
| Date of interim/final analysis                       | 16 March 2022 |
| Is this the analysis of the primary completion data? | No            |
| Global end of trial reached?                         | Yes           |
| Global end of trial date                             | 16 March 2022 |
| Was the trial ended prematurely?                     | Yes           |

Notes:

## General information about the trial

Main objective of the trial:

- To evaluate the efficacy of GWP42003 P versus placebo after 12 weeks of treatment
- To evaluate the safety and tolerability of GWP42003 P

Protection of trial subjects:

This study was conducted in accordance with the protocol and consensus ethical principles derived from international guidelines including the Declaration of Helsinki, the ICH Harmonised Guideline: Integrated Addendum to ICH E6(R1): Guideline for GCP E6(R2), the EU Clinical Trials Directive, the EU GCP Directive and the clinical study regulations adopting European Commission Directives into national legislation.

The protocol, protocol amendments, informed consent form, Investigator's Brochure, and other relevant documents (eg, advertisements) were submitted to the Institutional Review Board/Independent Ethics Committee (IRB/IEC) by the investigator and reviewed and approved by the IRB/IEC before the study was initiated.

Background therapy: -

Evidence for comparator: -

|   |                |
|---|----------------|
| Actual start date of recruitment                          | 18 August 2020 |
| Long term follow-up planned                               | No             |
| Independent data monitoring committee (IDMC) involvement? | No             |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                   |
|--------------------------------------|-------------------|
| Country: Number of subjects enrolled | Poland: 3         |
| Country: Number of subjects enrolled | Spain: 3          |
| Country: Number of subjects enrolled | United States: 68 |
| Country: Number of subjects enrolled | Serbia: 21        |
| Worldwide total number of subjects   | 95                |
| EEA total number of subjects         | 6                 |

Notes:

### Subjects enrolled per age group

|   |   |
|---|---|
| In utero                                  | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days)                      | 0 |

|  |    |
|--|----|
| Infants and toddlers (28 days-23 months) | 0  |
| Children (2-11 years)                    | 0  |
| Adolescents (12-17 years)                | 0  |
| Adults (18-64 years)                     | 95 |
| From 65 to 84 years                      | 0  |
| 85 years and over                        | 0  |

## Subject disposition

### Recruitment

Recruitment details:

A total of 95 participants who met all inclusion and no exclusion criteria were enrolled in the study and were randomized to the Placebo Run-in Period. Eighteen participants failed the Placebo Run-in Period. A total of 77 participants were randomized to 1 of 2 GWP42003-P doses or placebo treatment at a 2:2:1:1 ratio at 33 clinic centers.

### Pre-assignment

Screening details:

Once enrolled, participants were randomized to treatment following a single-blind, 2-week Placebo Run-in Period. A total of 95 participants were included the Placebo Run-in Period; 18 participants failed the Placebo Run-in Period. A total of 77 participants were randomized to the Treatment Period.

### Period 1

|                              |                                  |
|------------------------------|----------------------------------|
| Period 1 title               | Randomized Placebo Run-in Period |
| Is this the baseline period? | No                               |
| Allocation method            | Randomised - controlled          |
| Blinding used                | Double blind                     |
| Roles blinded                | Subject, Investigator            |

### Arms

|                  |                |
|------------------|----------------|
| <b>Arm title</b> | Pooled Placebo |
|------------------|----------------|

Arm description:

Clinically stable schizophrenia participants experiencing inadequate response to antipsychotic treatment who were randomized to receive a matching placebo per day for 12 weeks.

|  |               |
|--|---------------|
| Arm type                               | Placebo       |
| Investigational medicinal product name | Placebo       |
| Investigational medicinal product code |               |
| Other name                             |               |
| Pharmaceutical forms                   | Oral solution |
| Routes of administration               | Oral use      |

Dosage and administration details:

Oral dose of matched placebo

|                                       |                |
|---------------------------------------|----------------|
| <b>Number of subjects in period 1</b> | Pooled Placebo |
| Started                               | 95             |
| Completed                             | 77             |
| Not completed                         | 18             |
| Placebo run-in failures               | 18             |

**Period 2**

|                              |                             |
|------------------------------|-----------------------------|
| Period 2 title               | Randomized Treatment Period |
| Is this the baseline period? | Yes <sup>[1]</sup>          |
| Allocation method            | Randomised - controlled     |
| Blinding used                | Double blind                |
| Roles blinded                | Subject, Investigator       |

**Arms**

|                              |     |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

|                  |                   |
|------------------|-------------------|
| <b>Arm title</b> | GWP42003-P 300 mg |
|------------------|-------------------|

## Arm description:

Clinically stable schizophrenia participants experiencing inadequate response to antipsychotic treatment who were randomized to receive an oral dose of GWP42003-P 300 milligrams (mg) per day for 12 weeks.

|  |               |
|--|---------------|
| Arm type                               | Experimental  |
| Investigational medicinal product name | GWP42003-P    |
| Investigational medicinal product code |               |
| Other name                             |               |
| Pharmaceutical forms                   | Oral solution |
| Routes of administration               | Oral use      |

## Dosage and administration details:

Oral dose of GWP42003-P 150 mg administered twice daily

|                  |                    |
|------------------|--------------------|
| <b>Arm title</b> | GWP42003-P 1000 mg |
|------------------|--------------------|

## Arm description:

Clinically stable schizophrenia participants experiencing inadequate response to antipsychotic treatment who were randomized to receive an oral dose of GWP42003-P 1000 milligrams (mg) per day for 12 weeks.

|  |               |
|--|---------------|
| Arm type                               | Experimental  |
| Investigational medicinal product name | GWP42003-P    |
| Investigational medicinal product code |               |
| Other name                             |               |
| Pharmaceutical forms                   | Oral solution |
| Routes of administration               | Oral use      |

## Dosage and administration details:

Oral dose of GWP42003-P 500 mg administered twice daily

|                  |                |
|------------------|----------------|
| <b>Arm title</b> | Pooled Placebo |
|------------------|----------------|

## Arm description:

Clinically stable schizophrenia participants experiencing inadequate response to antipsychotic treatment who were randomized to receive a matching placebo per day for 12 weeks.

|  |               |
|--|---------------|
| Arm type                               | Placebo       |
| Investigational medicinal product name | Placebo       |
| Investigational medicinal product code |               |
| Other name                             |               |
| Pharmaceutical forms                   | Oral solution |
| Routes of administration               | Oral use      |

## Dosage and administration details:

Oral dose of matched placebo

## Notes:

[1] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period.

Justification: The baseline period is the Treatment Period where patients were randomized to either GWP42003-P (300 mg or 1000 mg) or placebo.

| <b>Number of subjects in period 2<sup>[2]</sup></b> | <b>GWP42003-P 300 mg</b> | <b>GWP42003-P 1000 mg</b> | <b>Pooled Placebo</b> |
|---|--------------------------|---------------------------|-----------------------|
| Started   | 27                       | 24                        | 26                    |
| Completed   | 23                       | 19                        | 19                    |
| Not completed                                       | 4                        | 5                         | 7                     |
| Withdrawal of parent/legal representative consent   | 1                        | -                         | 1                     |
| Adverse event, non-fatal                            | -                        | 1                         | -                     |
| Not specified                                       | -                        | 1                         | 3                     |
| Lost to follow-up                                   | 2                        | 2                         | 1                     |
| Participant non-compliance                          | 1                        | 1                         | 2                     |

Notes:

[2] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: The worldwide number of patients included 95 participants who were enrolled in the study and randomized to the Placebo Run-in Period. Eighteen participants failed the Placebo Run-in Period. Therefore, a total of 77 participants were randomized to the Treatment Period and is considered the baseline period.

## Baseline characteristics

### Reporting groups

|   |                    |
|---|--------------------|
| Reporting group title   | GWP42003-P 300 mg  |
| Reporting group description:<br>Clinically stable schizophrenia participants experiencing inadequate response to antipsychotic treatment who were randomized to receive an oral dose of GWP42003-P 300 milligrams (mg) per day for 12 weeks.  |                    |
| Reporting group title   | GWP42003-P 1000 mg |
| Reporting group description:<br>Clinically stable schizophrenia participants experiencing inadequate response to antipsychotic treatment who were randomized to receive an oral dose of GWP42003-P 1000 milligrams (mg) per day for 12 weeks. |                    |
| Reporting group title   | Pooled Placebo     |
| Reporting group description:<br>Clinically stable schizophrenia participants experiencing inadequate response to antipsychotic treatment who were randomized to receive a matching placebo per day for 12 weeks.                              |                    |

| Reporting group values                             | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo |
|--|-------------------|--------------------|----------------|
| Number of subjects                                 | 27                | 24                 | 26             |
| Age categorical<br>Units: Subjects                 |                   |                    |                |
| In utero   | 0                 | 0                  | 0              |
| Preterm newborn infants (gestational age < 37 wks) | 0                 | 0                  | 0              |
| Newborns (0-27 days)                               | 0                 | 0                  | 0              |
| Infants and toddlers (28 days-23 months)           | 0                 | 0                  | 0              |
| Children (2-11 years)                              | 0                 | 0                  | 0              |
| Adolescents (12-17 years)                          | 0                 | 0                  | 0              |
| Adults (18-64 years)                               | 27                | 24                 | 26             |
| From 65-84 years                                   | 0                 | 0                  | 0              |
| 85 years and over                                  | 0                 | 0                  | 0              |
| Age continuous<br>Units: years                     |                   |                    |                |
| arithmetic mean                                    | 37.5              | 39.2               | 38.7           |
| standard deviation                                 | ± 7.53            | ± 8.21             | ± 8.87         |
| Gender categorical<br>Units: Subjects              |                   |                    |                |
| Female   | 6                 | 7                  | 7              |
| Male   | 21                | 17                 | 19             |

| Reporting group values                             | Total |  |  |
|--|-------|--|--|
| Number of subjects                                 | 77    |  |  |
| Age categorical<br>Units: Subjects                 |       |  |  |
| In utero   | 0     |  |  |
| Preterm newborn infants (gestational age < 37 wks) | 0     |  |  |
| Newborns (0-27 days)                               | 0     |  |  |

|   |    |  |  |
|---|----|--|--|
| Infants and toddlers (28 days-23 months)                                | 0  |  |  |
| Children (2-11 years)   | 0  |  |  |
| Adolescents (12-17 years)   | 0  |  |  |
| Adults (18-64 years)  | 77 |  |  |
| From 65-84 years  | 0  |  |  |
| 85 years and over   | 0  |  |  |
| Age continuous<br>Units: years<br>arithmetic mean<br>standard deviation | -  |  |  |
| Gender categorical<br>Units: Subjects                                   |    |  |  |
| Female  | 20 |  |  |
| Male  | 57 |  |  |



## End points

### End points reporting groups

|   |                    |
|---|--------------------|
| Reporting group title   | Pooled Placebo     |
| Reporting group description:<br>Clinically stable schizophrenia participants experiencing inadequate response to antipsychotic treatment who were randomized to receive a matching placebo per day for 12 weeks.                              |                    |
| Reporting group title   | GWP42003-P 300 mg  |
| Reporting group description:<br>Clinically stable schizophrenia participants experiencing inadequate response to antipsychotic treatment who were randomized to receive an oral dose of GWP42003-P 300 milligrams (mg) per day for 12 weeks.  |                    |
| Reporting group title   | GWP42003-P 1000 mg |
| Reporting group description:<br>Clinically stable schizophrenia participants experiencing inadequate response to antipsychotic treatment who were randomized to receive an oral dose of GWP42003-P 1000 milligrams (mg) per day for 12 weeks. |                    |
| Reporting group title   | Pooled Placebo     |
| Reporting group description:<br>Clinically stable schizophrenia participants experiencing inadequate response to antipsychotic treatment who were randomized to receive a matching placebo per day for 12 weeks.                              |                    |

### Primary: Least Square Mean Change From Baseline in the Positive and Negative Symptoms Scale Total (PANSS-T) Score

|  |  |
|--|--|
| End point title  | Least Square Mean Change From Baseline in the Positive and Negative Symptoms Scale Total (PANSS-T) Score |
| End point description:<br>The PANSS-T is a medical scale used for measuring symptom severity of participants with schizophrenia or related psychotic disorder. It is a 30-item rating instrument that assesses the positive and negative symptoms of schizophrenia as well as symptoms of general psychopathology. Individual items are rated on a 7-point scale, where 1 = absent and 7 = extreme. A PANSS-T score is derived from the sum of the 30 items and the total score ranges from 30 to 210, where higher scores represent worse outcome. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome. |  |
| End point type   | Primary  |
| End point timeframe:<br>Baseline up to Week 12   |  |

| End point values                    | GWP42003-P 300 mg    | GWP42003-P 1000 mg   | Pooled Placebo      |  |
|-------------------------------------|----------------------|----------------------|---------------------|--|
| Subject group type                  | Reporting group      | Reporting group      | Reporting group     |  |
| Number of subjects analysed         | 23                   | 19                   | 19                  |  |
| Units: units on a scale             |                      |                      |                     |  |
| least squares mean (standard error) |                      |                      |                     |  |
| PANSS-T Score                       | -10.49 ( $\pm$ 1.64) | -10.69 ( $\pm$ 1.75) | -8.74 ( $\pm$ 1.78) |  |

## Statistical analyses

|   |                                       |
|---|---------------------------------------|
| <b>Statistical analysis title</b>       | GWP42003-P 300 mg vs Pooled placebo   |
| Comparison groups                       | GWP42003-P 300 mg v Pooled Placebo    |
| Number of subjects included in analysis | 42                                    |
| Analysis specification                  | Pre-specified                         |
| Analysis type                           | superiority <sup>[1]</sup>            |
| P-value                                 | = 0.4528                              |
| Method                                  | Mixed-effects repeated measures model |
| Parameter estimate                      | Least square mean difference          |
| Point estimate                          | -1.75                                 |
| Confidence interval                     |                                       |
| level                                   | 95 %                                  |
| sides                                   | 2-sided                               |
| lower limit                             | -6.35                                 |
| upper limit                             | 2.84                                  |
| Variability estimate                    | Standard error of the mean            |
| Dispersion value                        | 2.33                                  |

Notes:

[1] - The repeated measures model includes stratification factors (sex and region), associated baseline, visit, randomised treatment arm and visit by treatment arm interaction as fixed effects and visit repeated within each participant as a repeated effect. For the PANSS-T score, baseline PANSS-P, baseline PANSS-N, and baseline PANSS-G are included in the model as fixed effects for the associated baseline instead of baseline PANSS-T.

|   |                                       |
|---|---------------------------------------|
| <b>Statistical analysis title</b>       | GWP42003-P 1000 mg vs Pooled placebo  |
| Comparison groups                       | GWP42003-P 1000 mg v Pooled Placebo   |
| Number of subjects included in analysis | 38                                    |
| Analysis specification                  | Pre-specified                         |
| Analysis type                           | superiority <sup>[2]</sup>            |
| P-value                                 | = 0.4226                              |
| Method                                  | Mixed-effects repeated measures model |
| Parameter estimate                      | Least square mean difference          |
| Point estimate                          | -1.96                                 |
| Confidence interval                     |                                       |
| level                                   | 95 %                                  |
| sides                                   | 2-sided                               |
| lower limit                             | -6.76                                 |
| upper limit                             | 2.85                                  |
| Variability estimate                    | Standard error of the mean            |
| Dispersion value                        | 2.44                                  |

Notes:

[2] - The repeated measures model includes stratification factors (sex and region), associated baseline, visit, randomised treatment arm and visit by treatment arm interaction as fixed effects and visit repeated within each participant as a repeated effect. For the PANSS-T score, baseline PANSS-P, baseline PANSS-N, and baseline PANSS-G are included in the model as fixed effects for the associated baseline instead of baseline PANSS-T.

## Primary: Least Square Mean Change From Baseline in the PANSS Positive Subscale (PANSS-P) Score

|                 |   |
|-----------------|---|
| End point title | Least Square Mean Change From Baseline in the PANSS Positive Subscale (PANSS-P) Score |
|-----------------|---|

End point description:

The PANSS 'P' Scale was calculated as the sum of the items prefixed with an P, 7 items in total, i.e. delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution and hostility. Individual items are rated on a 7-point scale, where 1 = absent

and 7 = extreme. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.

|                        |         |
|------------------------|---------|
| End point type         | Primary |
| End point timeframe:   |         |
| Baseline up to Week 12 |         |

| End point values                    | GWP42003-P<br>300 mg | GWP42003-P<br>1000 mg | Pooled Placebo  |  |
|-------------------------------------|----------------------|-----------------------|-----------------|--|
| Subject group type                  | Reporting group      | Reporting group       | Reporting group |  |
| Number of subjects analysed         | 23                   | 19                    | 19              |  |
| Units: units on a scale             |                      |                       |                 |  |
| least squares mean (standard error) |                      |                       |                 |  |
| PANSS-P Score                       | -3.16 (± 0.59)       | -3.75 (± 0.63)        | -2.53 (± 0.62)  |  |

## Statistical analyses

|   |                                       |
|---|---------------------------------------|
| <b>Statistical analysis title</b>       | GWP42003-P 300 mg vs Pooled Placebo   |
| Comparison groups                       | Pooled Placebo v GWP42003-P 300 mg    |
| Number of subjects included in analysis | 42                                    |
| Analysis specification                  | Pre-specified                         |
| Analysis type                           | superiority <sup>[3]</sup>            |
| P-value                                 | = 0.4479                              |
| Method                                  | Mixed-effects repeated measures model |
| Parameter estimate                      | Least square mean difference          |
| Point estimate                          | -0.63                                 |
| Confidence interval                     |                                       |
| level                                   | 95 %                                  |
| sides                                   | 2-sided                               |
| lower limit                             | -2.25                                 |
| upper limit                             | 1                                     |
| Variability estimate                    | Standard error of the mean            |
| Dispersion value                        | 0.83                                  |

Notes:

[3] - The repeated measures model includes stratification factors (sex and region), associated baseline, visit, randomised treatment arm and visit by treatment arm interaction as fixed effects and visit repeated within each participant as a repeated effect.

|   |                                       |
|---|---------------------------------------|
| <b>Statistical analysis title</b>       | GWP42003-P 1000 mg vs Pooled Placebo  |
| Comparison groups                       | GWP42003-P 1000 mg v Pooled Placebo   |
| Number of subjects included in analysis | 38                                    |
| Analysis specification                  | Pre-specified                         |
| Analysis type                           | superiority <sup>[4]</sup>            |
| P-value                                 | = 0.1616                              |
| Method                                  | Mixed-effects repeated measures model |
| Parameter estimate                      | Least square mean difference          |
| Point estimate                          | -1.22                                 |

|                      |                            |
|----------------------|----------------------------|
| Confidence interval  |                            |
| level                | 95 %                       |
| sides                | 2-sided                    |
| lower limit          | -2.92                      |
| upper limit          | 0.49                       |
| Variability estimate | Standard error of the mean |
| Dispersion value     | 0.87                       |

Notes:

[4] - The repeated measures model includes stratification factors (sex and region), associated baseline, visit, randomised treatment arm and visit by treatment arm interaction as fixed effects and visit repeated within each participant as a repeated effect.

### Primary: Least Square Mean Change From Baseline in the PANSS Negative Subscale (PANSS-N) Score

|                 |   |
|-----------------|---|
| End point title | Least Square Mean Change From Baseline in the PANSS Negative Subscale (PANSS-N) Score |
|-----------------|---|

End point description:

The PANSS 'N' Scale will be calculated as the sum of the items prefixed with an N, 7 items in total, i.e. blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation and stereotyped thinking. Individual items are rated on a 7-point scale, where 1 = absent and 7 = extreme. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline up to Week 12

| End point values                    | GWP42003-P<br>300 mg | GWP42003-P<br>1000 mg | Pooled Placebo  |  |
|-------------------------------------|----------------------|-----------------------|-----------------|--|
| Subject group type                  | Reporting group      | Reporting group       | Reporting group |  |
| Number of subjects analysed         | 23                   | 19                    | 19              |  |
| Units: units on a scale             |                      |                       |                 |  |
| least squares mean (standard error) |                      |                       |                 |  |
| PANSS-N Score                       | -2.64 (± 0.53)       | -1.57 (± 0.56)        | -2.33 (± 0.58)  |  |

### Statistical analyses

|   |                                       |
|---|---------------------------------------|
| <b>Statistical analysis title</b>       | GWP42003-P 300 mg vs Pooled Placebo   |
| Comparison groups                       | GWP42003-P 300 mg v Pooled Placebo    |
| Number of subjects included in analysis | 42                                    |
| Analysis specification                  | Pre-specified                         |
| Analysis type                           | superiority <sup>[5]</sup>            |
| P-value                                 | = 0.6787                              |
| Method                                  | Mixed-effects repeated measures model |
| Parameter estimate                      | Least square mean difference          |
| Point estimate                          | -0.31                                 |

|                      |                            |
|----------------------|----------------------------|
| Confidence interval  |                            |
| level                | 95 %                       |
| sides                | 2-sided                    |
| lower limit          | -1.8                       |
| upper limit          | 1.18                       |
| Variability estimate | Standard error of the mean |
| Dispersion value     | 0.76                       |

Notes:

[5] - The repeated measures model includes stratification factors (sex and region), associated baseline, visit, randomised treatment arm and visit by treatment arm interaction as fixed effects and visit repeated within each participant as a repeated effect.

|   |                                       |
|---|---------------------------------------|
| <b>Statistical analysis title</b>       | GWP42003-P 1000 mg vs Pooled Placebo  |
| Comparison groups                       | GWP42003-P 1000 mg v Pooled Placebo   |
| Number of subjects included in analysis | 38                                    |
| Analysis specification                  | Pre-specified                         |
| Analysis type                           | superiority <sup>[6]</sup>            |
| P-value                                 | = 0.3351                              |
| Method                                  | Mixed-effects repeated measures model |
| Parameter estimate                      | Least square mean difference          |
| Point estimate                          | 0.76                                  |
| Confidence interval                     |                                       |
| level                                   | 95 %                                  |
| sides                                   | 2-sided                               |
| lower limit                             | -0.79                                 |
| upper limit                             | 2.3                                   |
| Variability estimate                    | Standard error of the mean            |
| Dispersion value                        | 0.78                                  |

Notes:

[6] - The repeated measures model includes stratification factors (sex and region), associated baseline, visit, randomised treatment arm and visit by treatment arm interaction as fixed effects and visit repeated within each participant as a repeated effect.

### **Primary: Least Square Mean Change From Baseline in the PANSS General Subscale (PANSS-G) Score**

|                 |  |
|-----------------|--|
| End point title | Least Square Mean Change From Baseline in the PANSS General Subscale (PANSS-G) Score |
|-----------------|--|

End point description:

The PANSS 'G' Scale will be calculated as the sum of the items prefixed with a G, 16 items in total, i.e. somatic concerns, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation and active social avoidance. Individual items are rated on a 7-point scale, where 1 = absent and 7 = extreme. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline up to Week 12

| End point values                    | GWP42003-P<br>300 mg | GWP42003-P<br>1000 mg | Pooled Placebo  |  |
|-------------------------------------|----------------------|-----------------------|-----------------|--|
| Subject group type                  | Reporting group      | Reporting group       | Reporting group |  |
| Number of subjects analysed         | 23                   | 19                    | 19              |  |
| Units: units on a scale             |                      |                       |                 |  |
| least squares mean (standard error) |                      |                       |                 |  |
| PANSS-G Score                       | -4.78 (± 1.03)       | -4.91 (± 1.10)        | -3.68 (± 1.09)  |  |

## Statistical analyses

|   |                                       |
|---|---------------------------------------|
| <b>Statistical analysis title</b>       | GWP42003-P 300 mg vs Pooled Placebo   |
| Comparison groups                       | GWP42003-P 300 mg v Pooled Placebo    |
| Number of subjects included in analysis | 42                                    |
| Analysis specification                  | Pre-specified                         |
| Analysis type                           | superiority <sup>[7]</sup>            |
| P-value                                 | = 0.4504                              |
| Method                                  | Mixed-effects repeated measures model |
| Parameter estimate                      | Least square mean difference          |
| Point estimate                          | -1.1                                  |
| Confidence interval                     |                                       |
| level                                   | 95 %                                  |
| sides                                   | 2-sided                               |
| lower limit                             | -3.96                                 |
| upper limit                             | 1.76                                  |
| Variability estimate                    | Standard error of the mean            |
| Dispersion value                        | 1.45                                  |

Notes:

[7] - The repeated measures model includes stratification factors (sex and region), associated baseline, visit, randomised treatment arm and visit by treatment arm interaction as fixed effects and visit repeated within each participant as a repeated effect.

|   |                                       |
|---|---------------------------------------|
| <b>Statistical analysis title</b>       | GWP42003-P 1000 mg vs Pooled Placebo  |
| Comparison groups                       | GWP42003-P 1000 mg v Pooled Placebo   |
| Number of subjects included in analysis | 38                                    |
| Analysis specification                  | Pre-specified                         |
| Analysis type                           | superiority <sup>[8]</sup>            |
| P-value                                 | = 0.4195                              |
| Method                                  | Mixed-effects repeated measures model |
| Parameter estimate                      | Least square mean difference          |
| Point estimate                          | -1.23                                 |
| Confidence interval                     |                                       |
| level                                   | 95 %                                  |
| sides                                   | 2-sided                               |
| lower limit                             | -4.22                                 |
| upper limit                             | 1.76                                  |
| Variability estimate                    | Standard error of the mean            |
| Dispersion value                        | 1.52                                  |

Notes:

[8] - The repeated measures model includes stratification factors (sex and region), associated baseline, visit, randomised treatment arm and visit by treatment arm interaction as fixed effects and visit repeated within each participant as a repeated effect.

---

**Primary: Least Square Mean Change From Baseline in the Clinical Global Impression of Severity (CGI-S) Score**

---

|                 |  |
|-----------------|--|
| End point title | Least Square Mean Change From Baseline in the Clinical Global Impression of Severity (CGI-S) Score |
|-----------------|--|

End point description:

The CGI-S is a 7-point scale used to rate the severity of participants' illness at the time of assessment. Considering total clinical experience, a participant will be assessed on severity of mental illness at the time of rating 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; or 7 = among the most extremely ill participants. The least square mean change from baseline is being reported and negative values indicate an improvement in outcome.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline up to Week 12

---

| End point values                    | GWP42003-P<br>300 mg | GWP42003-P<br>1000 mg | Pooled Placebo  |  |
|-------------------------------------|----------------------|-----------------------|-----------------|--|
| Subject group type                  | Reporting group      | Reporting group       | Reporting group |  |
| Number of subjects analysed         | 23                   | 19                    | 19              |  |
| Units: units on a scale             |                      |                       |                 |  |
| least squares mean (standard error) |                      |                       |                 |  |
| CGI-S Score                         | -0.47 (± 0.11)       | -0.50 (± 0.12)        | -0.45 (± 0.12)  |  |

**Statistical analyses**

|   |                                       |
|---|---------------------------------------|
| <b>Statistical analysis title</b>       | GWP42003-P 300 mg vs Pooled Placebo   |
| Comparison groups                       | GWP42003-P 300 mg v Pooled Placebo    |
| Number of subjects included in analysis | 42                                    |
| Analysis specification                  | Pre-specified                         |
| Analysis type                           | superiority <sup>[9]</sup>            |
| P-value                                 | = 0.885                               |
| Method                                  | Mixed-effects repeated measures model |
| Parameter estimate                      | Least square mean difference          |
| Point estimate                          | 0.02                                  |
| Confidence interval                     |                                       |
| level                                   | 95 %                                  |
| sides                                   | 2-sided                               |
| lower limit                             | -0.35                                 |
| upper limit                             | 0.3                                   |
| Variability estimate                    | Standard error of the mean            |
| Dispersion value                        | 0.16                                  |

Notes:

[9] - The repeated measures model includes stratification factors (sex and region), associated baseline, visit, randomised treatment arm, visit by treatment arm interaction and visit by associated baseline interaction as fixed effects and visit repeated within each participant as a repeated effect.

|   |                                       |
|---|---------------------------------------|
| <b>Statistical analysis title</b>       | GWP42003-P 1000 mg vs Pooled Placebo  |
| Comparison groups                       | GWP42003-P 1000 mg v Pooled Placebo   |
| Number of subjects included in analysis | 38                                    |
| Analysis specification                  | Pre-specified                         |
| Analysis type                           | superiority <sup>[10]</sup>           |
| P-value                                 | = 0.7808                              |
| Method                                  | Mixed-effects repeated measures model |
| Parameter estimate                      | Least square mean difference          |
| Point estimate                          | 0.04                                  |
| Confidence interval                     |                                       |
| level                                   | 95 %                                  |
| sides                                   | 2-sided                               |
| lower limit                             | -0.36                                 |
| upper limit                             | 0.27                                  |
| Variability estimate                    | Standard error of the mean            |
| Dispersion value                        | 0.16                                  |

Notes:

[10] - The repeated measures model includes stratification factors (sex and region), associated baseline, visit, randomised treatment arm, visit by treatment arm interaction and visit by associated baseline interaction as fixed effects and visit repeated within each participant as a repeated effect.

### **Primary: Number of Participants With Minimally or Better Clinical Global Impression of Improvement (CGI-I) Score at Week 12**

|                 |  |
|-----------------|--|
| End point title | Number of Participants With Minimally or Better Clinical Global Impression of Improvement (CGI-I) Score at Week 12 |
|-----------------|--|

End point description:

The CGI-I is a 7-point scale used to rate the improvement of participants' condition at the time of assessment. Compared to the patient's condition at baseline, the participants' condition was rated as 1 = very much improved since initiation of treatment; 2 = much improved; 3 = minimally improved; 4 = no change from baseline; 5 = minimally worse; 6 = much worse; 7 = very much worse since the initiation of treatment. Higher scores indicate a worse outcome. The number of participants with minimally or better improvements (score of 3 or better) are being reported.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Week 12

| <b>End point values</b>         | GWP42003-P<br>300 mg | GWP42003-P<br>1000 mg | Pooled Placebo  |  |
|---------------------------------|----------------------|-----------------------|-----------------|--|
| Subject group type              | Reporting group      | Reporting group       | Reporting group |  |
| Number of subjects analysed     | 23                   | 19                    | 19              |  |
| Units: number of participants   |                      |                       |                 |  |
| number (not applicable)         |                      |                       |                 |  |
| Minimally or Better CGI-I Score | 17                   | 12                    | 15              |  |

### **Statistical analyses**

|                                   |                                     |
|-----------------------------------|-------------------------------------|
| <b>Statistical analysis title</b> | GWP42003-P 300 mg vs Pooled Placebo |
| Comparison groups                 | GWP42003-P 300 mg v Pooled Placebo  |



|   |                      |
|---|----------------------|
| Number of subjects included in analysis | 42                   |
| Analysis specification                  | Pre-specified        |
| Analysis type                           | superiority          |
| P-value                                 | = 0.6707             |
| Method                                  | Regression, Logistic |
| Parameter estimate                      | Odds ratio (OR)      |
| Point estimate                          | 1.412                |
| Confidence interval                     |                      |
| level                                   | 95 %                 |
| sides                                   | 2-sided              |
| lower limit                             | 0.288                |
| upper limit                             | 6.924                |

|   |                                      |
|---|--------------------------------------|
| <b>Statistical analysis title</b>       | GWP42003-P 1000 mg vs Pooled Placebo |
| Comparison groups                       | GWP42003-P 1000 mg v Pooled Placebo  |
| Number of subjects included in analysis | 38                                   |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           | superiority                          |
| P-value                                 | = 0.4883                             |
| Method                                  | Regression, Logistic                 |
| Parameter estimate                      | Odds ratio (OR)                      |
| Point estimate                          | 0.576                                |
| Confidence interval                     |                                      |
| level                                   | 95 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | 0.121                                |
| upper limit                             | 2.744                                |

### Secondary: Mean Change From Baseline in Body Weight

|                        |  |
|------------------------|--|
| End point title        | Mean Change From Baseline in Body Weight |
| End point description: |  |
| End point type         | Secondary                                |
| End point timeframe:   |  |
| Baseline up to Week 12 |  |

| End point values                     | GWP42003-P<br>300 mg | GWP42003-P<br>1000 mg | Pooled Placebo  |  |
|--------------------------------------|----------------------|-----------------------|-----------------|--|
| Subject group type                   | Reporting group      | Reporting group       | Reporting group |  |
| Number of subjects analysed          | 23                   | 19                    | 19              |  |
| Units: kg                            |                      |                       |                 |  |
| arithmetic mean (standard deviation) |                      |                       |                 |  |
| Body weight                          | -0.03 (± 3.09)       | -0.14 (± 1.98)        | 1.37 (± 1.28)   |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Mean Change From Baseline in Body Mass Index (BMI)

|                 |  |
|-----------------|--|
| End point title | Mean Change From Baseline in Body Mass Index (BMI) |
|-----------------|--|

End point description:

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Week 12

| End point values                     | GWP42003-P<br>300 mg | GWP42003-P<br>1000 mg | Pooled Placebo  |  |
|--------------------------------------|----------------------|-----------------------|-----------------|--|
| Subject group type                   | Reporting group      | Reporting group       | Reporting group |  |
| Number of subjects analysed          | 23                   | 19                    | 19              |  |
| Units: kg/m <sup>2</sup>             |                      |                       |                 |  |
| arithmetic mean (standard deviation) |                      |                       |                 |  |
| Body mass index                      | 0 (± 0.98)           | -0.04 (± 0.66)        | 0.45 (± 0.45)   |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Mean Change From Baseline in Waist Circumference

|                 |  |
|-----------------|--|
| End point title | Mean Change From Baseline in Waist Circumference |
|-----------------|--|

End point description:

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Week 12

| End point values                     | GWP42003-P<br>300 mg | GWP42003-P<br>1000 mg | Pooled Placebo  |  |
|--------------------------------------|----------------------|-----------------------|-----------------|--|
| Subject group type                   | Reporting group      | Reporting group       | Reporting group |  |
| Number of subjects analysed          | 23                   | 19                    | 19              |  |
| Units: centimeters                   |                      |                       |                 |  |
| arithmetic mean (standard deviation) |                      |                       |                 |  |
| Waist circumference                  | 0.41 (± 5.36)        | -0.53 (± 2.07)        | 1.34 (± 3.13)   |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Mean Change From Baseline in Blood Pressure

|                        |   |
|------------------------|---|
| End point title        | Mean Change From Baseline in Blood Pressure |
| End point description: |   |
| End point type         | Secondary                                   |
| End point timeframe:   |   |
| Baseline up to Week 12 |   |

| End point values                     | GWP42003-P<br>300 mg | GWP42003-P<br>1000 mg | Pooled Placebo  |  |
|--------------------------------------|----------------------|-----------------------|-----------------|--|
| Subject group type                   | Reporting group      | Reporting group       | Reporting group |  |
| Number of subjects analysed          | 23                   | 19                    | 19              |  |
| Units: mmHg                          |                      |                       |                 |  |
| arithmetic mean (standard deviation) |                      |                       |                 |  |
| Diastolic blood pressure             | 1.7 (± 6.19)         | 0 (± 7.05)            | -0.2 (± 5.71)   |  |
| Systolic blood pressure              | 0.3 (± 9.38)         | 0 (± 8.41)            | 0.3 (± 5.66)    |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Mean Change From Baseline in Heart Rate

|                        |   |
|------------------------|---|
| End point title        | Mean Change From Baseline in Heart Rate |
| End point description: |   |
| End point type         | Secondary                               |
| End point timeframe:   |   |
| Baseline up to Week 12 |   |

| End point values                     | GWP42003-P<br>300 mg | GWP42003-P<br>1000 mg | Pooled Placebo    |  |
|--------------------------------------|----------------------|-----------------------|-------------------|--|
| Subject group type                   | Reporting group      | Reporting group       | Reporting group   |  |
| Number of subjects analysed          | 23                   | 19                    | 19                |  |
| Units: beats/minute                  |                      |                       |                   |  |
| arithmetic mean (standard deviation) |                      |                       |                   |  |
| Heart rate                           | 1.0 ( $\pm$ 8.46)    | -3.1 ( $\pm$ 9.13)    | 0.1 ( $\pm$ 6.52) |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Mean Change From Baseline in Respiratory Rate

|                        |   |
|------------------------|---|
| End point title        | Mean Change From Baseline in Respiratory Rate |
| End point description: |   |
| End point type         | Secondary                                     |
| End point timeframe:   |   |
| Baseline up to Week 12 |   |

| End point values                     | GWP42003-P<br>300 mg | GWP42003-P<br>1000 mg | Pooled Placebo  |  |
|--------------------------------------|----------------------|-----------------------|-----------------|--|
| Subject group type                   | Reporting group      | Reporting group       | Reporting group |  |
| Number of subjects analysed          | 23                   | 19                    | 19              |  |
| Units: breaths/minute                |                      |                       |                 |  |
| arithmetic mean (standard deviation) |                      |                       |                 |  |
| Respiratory rate                     | -0.6 ( $\pm$ 2.13)   | 0.1 ( $\pm$ 1.37)     | 0 ( $\pm$ 1.45) |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Mean Change From Baseline in Temperature

|                        |  |
|------------------------|--|
| End point title        | Mean Change From Baseline in Temperature |
| End point description: |  |
| End point type         | Secondary                                |
| End point timeframe:   |  |
| Baseline up to Week 12 |  |

| End point values                     | GWP42003-P<br>300 mg | GWP42003-P<br>1000 mg | Pooled Placebo  |  |
|--------------------------------------|----------------------|-----------------------|-----------------|--|
| Subject group type                   | Reporting group      | Reporting group       | Reporting group |  |
| Number of subjects analysed          | 23                   | 19                    | 19              |  |
| Units: Celsius                       |                      |                       |                 |  |
| arithmetic mean (standard deviation) |                      |                       |                 |  |
| Temperature                          | -0.07 (± 0.34)       | 0.06 (± 0.20)         | -0.02 (± 0.19)  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Test Results

|                 |  |
|-----------------|--|
| End point title | Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Test Results |
|-----------------|--|

End point description:

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Week 12

| End point values                              | GWP42003-P<br>300 mg | GWP42003-P<br>1000 mg | Pooled Placebo  |  |
|---|----------------------|-----------------------|-----------------|--|
| Subject group type                            | Reporting group      | Reporting group       | Reporting group |  |
| Number of subjects analysed                   | 23                   | 19                    | 19              |  |
| Units: number of participants                 |                      |                       |                 |  |
| number (not applicable)                       |                      |                       |                 |  |
| Supine systolic blood pressure, Day 85: <-20  | 0                    | 0                     | 0               |  |
| Supine systolic blood pressure, Day 85: >20   | 1                    | 0                     | 0               |  |
| Supine diastolic blood pressure, Day 85: <-10 | 0                    | 1                     | 0               |  |
| Supine diastolic blood pressure, Day 85: >10  | 2                    | 1                     | 0               |  |
| Heart rate, Day 85: <-20                      | 0                    | 0                     | 0               |  |
| Heart rate, Day 85: >20                       | 0                    | 0                     | 0               |  |
| Weight, Day 85: ≤-7%                          | 2                    | 1                     | 0               |  |
| Weight, Day 85: ≥7%                           | 1                    | 0                     | 0               |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants With Defined Flagged Electrocardiogram (ECG)

## Parameter Values

|                 |  |
|-----------------|--|
| End point title | Number of Participants With Defined Flagged Electrocardiogram (ECG) Parameter Values |
|-----------------|--|

End point description:

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline up to Week 12

| End point values                 | GWP42003-P<br>300 mg | GWP42003-P<br>1000 mg | Pooled Placebo  |  |
|----------------------------------|----------------------|-----------------------|-----------------|--|
| Subject group type               | Reporting group      | Reporting group       | Reporting group |  |
| Number of subjects analysed      | 27                   | 24                    | 26              |  |
| Units: number of participants    |                      |                       |                 |  |
| number (not applicable)          |                      |                       |                 |  |
| QTcF interval, Day 85: >450 msec | 0                    | 1                     | 0               |  |
| QTcF interval, Day 85: >480 msec | 0                    | 0                     | 0               |  |
| QTcF interval, Day 85: >500 msec | 0                    | 0                     | 0               |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Suicidal Ideation or Behavior Based on The Columbia Suicide Severity Rating Scale (CSSRS)

|                 |   |
|-----------------|---|
| End point title | Number of Participants With Suicidal Ideation or Behavior Based on The Columbia Suicide Severity Rating Scale (CSSRS) |
|-----------------|---|

End point description:

The C-SSRS is a short questionnaire that is used to assess suicidal ideation (5 questions) and behavior (5 questions) since last patient visit. The questionnaire is completed by participants answering yes or no to each question.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (screening) up to Day 85

| End point values                                  | GWP42003-P<br>300 mg | GWP42003-P<br>1000 mg | Pooled Placebo  |  |
|---|----------------------|-----------------------|-----------------|--|
| Subject group type                                | Reporting group      | Reporting group       | Reporting group |  |
| Number of subjects analysed                       | 27                   | 24                    | 26              |  |
| Units: number of participants                     |                      |                       |                 |  |
| number (not applicable)                           |                      |                       |                 |  |
| Screening: Ideation, Wish to be dead              | 1                    | 0                     | 0               |  |
| Screening: Ideation, Non-specific active thoughts | 0                    | 0                     | 0               |  |
| Screening: Ideation, Active any method no intent  | 0                    | 0                     | 0               |  |

|  |   |   |   |  |
|--|---|---|---|--|
| Screening: Ideation, Active intent to act, no plan | 0 | 0 | 0 |  |
| Screening: Ideation, Active specific plan/intent   | 0 | 0 | 0 |  |
| Screening: Behavior, Preparatory acts or behavior  | 0 | 0 | 0 |  |
| Screening: Behavior, Aborted attempt               | 0 | 0 | 0 |  |
| Screening: Behavior, Interrupted attempt           | 0 | 0 | 0 |  |
| Screening: Behavior, Actual attempt                | 0 | 0 | 0 |  |
| Screening: Behavior, Completed suicide             | 0 | 0 | 0 |  |
| Day 14: Ideation, Wish to be dead                  | 0 | 1 | 0 |  |
| Day 14: Ideation, Non-specific active thoughts     | 0 | 0 | 0 |  |
| Day 14: Ideation, Active any method no intent      | 0 | 0 | 0 |  |
| Day 14: Ideation, Active intent to act, no plan    | 0 | 0 | 0 |  |
| Day 14: Ideation, Active specific plan/intent      | 0 | 0 | 0 |  |
| Day 14: Behavior, Preparatory acts or behavior     | 0 | 0 | 0 |  |
| Day 14: Behavior, Aborted attempt                  | 0 | 0 | 0 |  |
| Day 14: Behavior, Interrupted attempt              | 0 | 0 | 0 |  |
| Day 14: Behavior, Actual attempt                   | 0 | 0 | 0 |  |
| Day 14: Behavior, Completed suicide                | 0 | 0 | 0 |  |
| Day 29: Ideation, Wish to be dead                  | 1 | 1 | 0 |  |
| Day 29: Ideation, Non-specific active thoughts     | 0 | 1 | 0 |  |
| Day 29: Ideation, Active any method no intent      | 0 | 1 | 0 |  |
| Day 29: Ideation, Active intent to act, no plan    | 0 | 0 | 0 |  |
| Day 29: Ideation, Active specific plan/intent      | 0 | 0 | 0 |  |
| Day 29: Behavior, Preparatory acts or behavior     | 0 | 0 | 0 |  |
| Day 29: Behavior, Aborted attempt                  | 0 | 0 | 0 |  |
| Day 29: Behavior, Interrupted attempt              | 0 | 0 | 0 |  |
| Day 29: Behavior, Actual attempt                   | 0 | 0 | 0 |  |
| Day 29: Behavior, Completed suicide                | 0 | 0 | 0 |  |
| Day 85: Ideation, Wish to be dead                  | 0 | 0 | 0 |  |
| Day 85: Ideation, Non-specific active thoughts     | 0 | 0 | 0 |  |
| Day 85: Ideation, Active any method no intent      | 0 | 0 | 0 |  |
| Day 85: Ideation, Active intent to act, no plan    | 0 | 0 | 0 |  |
| Day 85: Ideation, Active specific plan/intent      | 0 | 0 | 0 |  |
| Day 85: Behavior, Preparatory acts or behavior     | 0 | 0 | 0 |  |
| Day 85: Behavior, Aborted attempt                  | 0 | 0 | 0 |  |
| Day 85: Behavior, Interrupted attempt              | 0 | 0 | 0 |  |
| Day 85: Behavior, Actual attempt                   | 0 | 0 | 0 |  |
| Day 85: Behavior, Completed suicide                | 0 | 0 | 0 |  |

## **Statistical analyses**

---

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All adverse events (AEs) were collected from baseline up to end of study, approximately 1 year 8 months.

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 24.1 |
|--------------------|------|

### Reporting groups

|                       |                   |
|-----------------------|-------------------|
| Reporting group title | GWP42003-P 300 mg |
|-----------------------|-------------------|

Reporting group description:

Clinically stable schizophrenia participants experiencing inadequate response to antipsychotic treatment who were randomized to receive an oral dose of GWP42003-P 300 milligrams (mg) per day for 12 weeks.

|                       |                    |
|-----------------------|--------------------|
| Reporting group title | GWP42003-P 1000 mg |
|-----------------------|--------------------|

Reporting group description:

Clinically stable schizophrenia participants experiencing inadequate response to antipsychotic treatment who were randomized to receive an oral dose of GWP42003-P 1000 milligrams (mg) per day for 12 weeks.

|                       |                                   |
|-----------------------|-----------------------------------|
| Reporting group title | Pooled Placebo (Treatment Period) |
|-----------------------|-----------------------------------|

Reporting group description:

Clinically stable schizophrenia participants experiencing inadequate response to antipsychotic treatment who were randomized to receive a matching placebo per day for 12 weeks.

|                       |  |
|-----------------------|--|
| Reporting group title | Pooled Placebo (Placebo Run-in Period) |
|-----------------------|--|

Reporting group description:

Clinically stable schizophrenia participants experiencing inadequate response to antipsychotic treatment who were randomized to receive a matching placebo for 2 weeks (including participants who failed the placebo run-in period).

| Serious adverse events                            | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo (Treatment Period) |
|---|-------------------|--------------------|-----------------------------------|
| Total subjects affected by serious adverse events |                   |                    |                                   |
| subjects affected / exposed                       | 2 / 27 (7.41%)    | 2 / 24 (8.33%)     | 1 / 26 (3.85%)                    |
| number of deaths (all causes)                     | 0                 | 0                  | 0                                 |
| number of deaths resulting from adverse events    | 0                 | 0                  | 0                                 |
| Surgical and medical procedures                   |                   |                    |                                   |
| Hospitalization                                   |                   |                    |                                   |
| subjects affected / exposed                       | 0 / 27 (0.00%)    | 0 / 24 (0.00%)     | 1 / 26 (3.85%)                    |
| occurrences causally related to treatment / all   | 0 / 0             | 0 / 0              | 0 / 1                             |
| deaths causally related to treatment / all        | 0 / 0             | 0 / 0              | 0 / 0                             |
| Skin and subcutaneous tissue disorders            |                   |                    |                                   |
| Urticaria   |                   |                    |                                   |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 27 (0.00%) | 1 / 24 (4.17%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 1 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| <b>Infections and infestations</b>              |                |                |                |
| COVID-19  |                |                |                |
| subjects affected / exposed                     | 2 / 27 (7.41%) | 0 / 24 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Coronavirus infection                           |                |                |                |
| subjects affected / exposed                     | 0 / 27 (0.00%) | 1 / 24 (4.17%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

|   |  |  |  |
|---|--|--|--|
| <b>Serious adverse events</b>                     | Pooled Placebo<br>(Placebo Run-in<br>Period) |  |  |
| Total subjects affected by serious adverse events |  |  |  |
| subjects affected / exposed                       | 0 / 95 (0.00%)                               |  |  |
| number of deaths (all causes)                     | 0  |  |  |
| number of deaths resulting from adverse events    | 0  |  |  |
| <b>Surgical and medical procedures</b>            |  |  |  |
| Hospitalization                                   |  |  |  |
| subjects affected / exposed                       | 0 / 95 (0.00%)                               |  |  |
| occurrences causally related to treatment / all   | 0 / 0  |  |  |
| deaths causally related to treatment / all        | 0 / 0  |  |  |
| <b>Skin and subcutaneous tissue disorders</b>     |  |  |  |
| Urticaria   |  |  |  |
| subjects affected / exposed                       | 0 / 95 (0.00%)                               |  |  |
| occurrences causally related to treatment / all   | 0 / 0  |  |  |
| deaths causally related to treatment / all        | 0 / 0  |  |  |
| <b>Infections and infestations</b>                |  |  |  |
| COVID-19  |  |  |  |
| subjects affected / exposed                       | 0 / 95 (0.00%)                               |  |  |
| occurrences causally related to treatment / all   | 0 / 0  |  |  |
| deaths causally related to treatment / all        | 0 / 0  |  |  |
| Coronavirus infection                             |  |  |  |

|   |                |  |  |
|---|----------------|--|--|
| subjects affected / exposed                     | 0 / 95 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>                     | GWP42003-P 300 mg | GWP42003-P 1000 mg | Pooled Placebo (Treatment Period) |
|---|-------------------|--------------------|-----------------------------------|
| Total subjects affected by non-serious adverse events |                   |                    |                                   |
| subjects affected / exposed                           | 3 / 27 (11.11%)   | 3 / 24 (12.50%)    | 3 / 26 (11.54%)                   |
| Nervous system disorders                              |                   |                    |                                   |
| Headache  |                   |                    |                                   |
| subjects affected / exposed                           | 1 / 27 (3.70%)    | 3 / 24 (12.50%)    | 3 / 26 (11.54%)                   |
| occurrences (all)                                     | 1                 | 3                  | 3                                 |
| Infections and infestations                           |                   |                    |                                   |
| COVID-19  |                   |                    |                                   |
| subjects affected / exposed                           | 2 / 27 (7.41%)    | 0 / 24 (0.00%)     | 0 / 26 (0.00%)                    |
| occurrences (all)                                     | 2                 | 0                  | 0                                 |

| <b>Non-serious adverse events</b>                     | Pooled Placebo (Placebo Run-in Period) |  |  |
|---|--|--|--|
| Total subjects affected by non-serious adverse events |  |  |  |
| subjects affected / exposed                           | 0 / 95 (0.00%)                         |  |  |
| Nervous system disorders                              |  |  |  |
| Headache  |  |  |  |
| subjects affected / exposed                           | 0 / 95 (0.00%)                         |  |  |
| occurrences (all)                                     | 0                                      |  |  |
| Infections and infestations                           |  |  |  |
| COVID-19  |  |  |  |
| subjects affected / exposed                           | 0 / 95 (0.00%)                         |  |  |
| occurrences (all)                                     | 0                                      |  |  |

**More information**

**Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

**Interruptions (globally)**

Were there any global interruptions to the trial? Yes

| Date          | Interruption  | Restart date |
|---------------|---|--------------|
| 16 March 2022 | The study was terminated based on a business decision by the Sponsor. | -            |

Notes:

**Limitations and caveats**

None reported